Metastasectomy Study in Renal Cell Carcinoma (RCC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00918775|
Recruitment Status : Recruiting
First Posted : June 11, 2009
Last Update Posted : May 31, 2017
|Condition or disease||Intervention/treatment|
|Kidney Cancer||Other: Evaluation|
This research study is designed to follow your progress after the surgery is complete. You will not receive any drugs or treatment as part of this research study. You may however receive non-study treatment after your surgery.
Every 6 months for 5 years after surgery, the following tests and procedures will be performed:
- You will have a physical exam, including measurement of your weight and vital signs.
- Your performance status will be recorded.
- Blood (about 2-3 teaspoons) and urine will be collected for routine tests.
- You will have CT scans or MRI scans of your chest, stomach area, and brain to check the status of the disease.
- If the study doctor thinks it is necessary, you will have a bone scan to check the status of the disease.
Length of Study:
You will have study visits for up to 5 years after the surgery is complete. You will be taken off study early if the disease gets worse, or if the study doctor thinks that it is no longer in your best interest to continue.
About every 6 months after your last study visit, the study staff will either review your medical records or contact you by phone or email to collect information about your health, to see how you are doing, and what anti-cancer treatments you may have received. If you are contacted by phone, the call should only last about 5 minutes each time.
This is an investigational study. Up to 120 patients will take part in this study. All will be enrolled at MD Anderson.
|Study Type :||Observational|
|Estimated Enrollment :||120 participants|
|Official Title:||A Phase II Metastasectomy Study for Patients With Renal Cell Carcinoma.|
|Actual Study Start Date :||June 9, 2009|
|Estimated Primary Completion Date :||June 2019|
|Estimated Study Completion Date :||June 2019|
Kidney cancer patients being considered for surgery
Evaluation during and after surgery: vital signs, performance status, physical exam, chest x-ray, CT and MRI plus health questions.
- 24-week Progression free/relapse free survival rate [ Time Frame: Every 3 months for the first year, every 4 months during the second year, every 6 months in the third through fifth year. ]Primary outcome is binary indicator that patient is alive with no evidence of disease progression (either progression or relapse) 24 weeks post surgery (response), denoted by Y. Time of surgery considered time 0. Baseline covariates examined for their ability to predict p = Pr(Y=1) include binary variables observed at first diagnosis, at trial entry, and type of therapeutic intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00918775
|Contact: Eric Jonasch, MD||713-792-2830|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Recruiting|
|Houston, Texas, United States, 77030|
|Study Chair:||Eric Jonasch, MD||M.D. Anderson Cancer Center|